SAMUEL MACHUCA: Open Payments
NPI 1801597372 · BELLAIRE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 15 payments from 10 companies in 2025. Trend: 2023 $57 · 2024 $141 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $154 |
| GENZYME CORPORATION | 1 | $122 |
| GlaxoSmithKline, LLC. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Verona Pharma, Inc. | 2 | $40 |
| Merck Sharp & Dohme LLC | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
Products named: BREZTRI, DUPIXENT, NUCALA, Ohtuvayre, PREVYMIS, FASENRA, ARALAST, OPSYNVI.
Industry payments across TX — which companies pay providers there.
